We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PYPD icon
201
PolyPid
PYPD
$98.1M
$528K 0.02%
103,950
– –
2025 Q4
2 quarters
LUNG icon
202
Pulmonx
LUNG
$76.4M
$526K 0.02%
404,497
+30,000
+8% +$41.3K
2025 Q2
4 quarters
MLTX icon
203
MoonLake Immunotherapeutics
MLTX
$863M
$526K 0.02%
27,000
-430,137
-94% -$7.8M
2026 Q1
1 quarter
GTERU icon
204
Globa Terra Acquisition Corp Units
GTERU
$520K 0.02%
50,000
– –
2025 Q3
3 quarters
TRAW icon
205
Traws Pharma
TRAW
$6.17M
$504K 0.02%
597,729
+443,631
+288% +$611K
2025 Q4
2 quarters
USFR icon
206
WisdomTree Floating Rate Treasury Fund
USFR
$20.8B
$504K 0.02%
10,000
– –
2023 Q4
10 quarters
TECX icon
207
Tectonic Therapeutic
TECX
$410M
$498K 0.02%
14,501
+1,500
+12% +$44.1K
2023 Q4
10 quarters
MDGL icon
208
Madrigal Pharmaceuticals
MDGL
$10.6B
$481K 0.02%
895
– –
2025 Q1
5 quarters
ARVN icon
209
Arvinas
ARVN
$446M
$479K 0.02%
57,591
– –
2025 Q1
5 quarters
KIDS icon
210
OrthoPediatrics
KIDS
$581M
$478K 0.02%
25,000
+5,155
+26% +$89.6K
2025 Q4
2 quarters
COGT icon
211
Cogent Biosciences
COGT
$4.88B
$472K 0.02%
+12,200
New +$427K
2026 Q2
0 quarters
PHAT icon
212
Phathom Pharmaceuticals
PHAT
$599M
$465K 0.02%
42,900
– –
2024 Q3
7 quarters
MIRM icon
213
Mirum Pharmaceuticals
MIRM
$5.19B
$457K 0.02%
3,900
-2,300
-37% -$231K
2026 Q1
1 quarter
KPRX icon
214
Kiora Pharmaceuticals
KPRX
$10.9M
$442K 0.02%
167,941
– –
2024 Q1
9 quarters
KURA icon
215
Kura Oncology
KURA
$855M
$439K 0.02%
40,000
– –
2025 Q1
5 quarters
CNTX icon
216
Context Therapeutics
CNTX
$23.5M
$416K 0.02%
750,969
+399,875
+114% +$811K
2024 Q1
9 quarters
STIP icon
217
iShares 0-5 Year TIPS Bond ETF
STIP
$16.5B
$409K 0.02%
+4,000
New +$413K
2026 Q2
0 quarters
KLRS icon
218
Kalaris Therapeutics
KLRS
$50.7M
$407K 0.02%
100,000
– –
2025 Q4
2 quarters
BCAX icon
219
Bicara Therapeutics
BCAX
$1.15B
$407K 0.02%
13,705
– –
2025 Q2
4 quarters
MRK icon
220
Merck
MRK
$364B
$403K 0.02%
3,140
– –
2025 Q2
4 quarters
NMRA icon
221
Neumora Therapeutics
NMRA
$66.6M
$357K 0.02%
210,000
+176,900
+534% +$337K
2025 Q4
2 quarters
IRTC icon
222
iRhythm Holdings
IRTC
$3.5B
$357K 0.02%
+3,000
New +$349K
2026 Q2
0 quarters
ACHV icon
223
Achieve Life Sciences
ACHV
$722M
$351K 0.02%
53,800
+6,000
+13% +$28.6K
2024 Q1
9 quarters
BABA icon
224
Alibaba
BABA
$277B
$343K 0.02%
3,578
– –
2025 Q3
3 quarters
WW icon
225
WW International
WW
$143M
$340K 0.02%
21,300
-36,400
-63% -$486K
2025 Q3
3 quarters
7 8
9
10 11

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.